Asia-Pacific Glaucoma Treatment Market Dominated By Top Companies - Novartis AG, Pfizer Inc., Allergan, Merck & Co., Ocular Therapeutix Inc, Ellex Etc. By 2023

Glaucoma is the buildup of pressure due to accumulation of eye fluids which may result in permanent blindness due to damage to the eye nerve endings. In fact, glaucoma is the second most reason after cataracts causing permanent blindness. Open angle glaucoma (OAG) is the most common type of glaucoma followed by closed angle glaucoma (CAG) and these two accounts for greater than 50% of glaucoma cases. Other types of glaucoma are pigmentary glaucoma, pseudoexfoliation glaucoma and normal-tension glaucoma.

The market for glaucoma treatment is growing due to factors such as rising geriatric population and rising cases of diseases such as diabetes. Other market drivers include increasing awareness, growing healthcare expenditure and screening rates.

The constraints of the market are excellent efficacy of the present drugs especially the prostaglandin analogs which are the market leaders. The other constraints are the low penetration of healthcare in poor regions of Asia, the neglect of eye care as compared to other healthcare sectors and the high cost of eye surgeries.

The market developments include the technological advancements in surgeries such as advanced technology glaucoma surgery (ATGS) which involves implant of a drainage device so as to drain the fluids. Micro-invasive glaucoma surgery (MIGS) drainage implants dominate the advanced technology glaucoma surgery (ATGS) devices and are expected to account for most of the growth.

Another development includes goggles that help normalize the difference between intraocular pressure (IOP) and cerebrospinal fluid.

Taking all factors into consideration, we expect the Asia Pacific glaucoma treatment market to reach around $ 888.94 million in 2023 from $576.0 million in 2017, by the end of the forecast period at a CAGR of ~ 7.5 %. While the glaucoma drug market will grow by a flat CAGR of 2.1% the glaucoma surgery market is poised for an explosive CAGR of 18.5 %.

Get Free Sample Report @ https://www.marketresearchfuture.com/sample_request/2962

Asia-Pacific Glaucoma Treatment Market – Key Players

The major participants of this market are: Novartis AG, Pfizer Inc., Allergan, Merck & Co., Ocular Therapeutix Inc, pSivida Corp, Icon Bioscience Inc, Amorphex Therapeutics LLC., Ellex, Quantel, Lumenis, and Lightmed and others.

Asia-Pacific Glaucoma Treatment Market – Regional Analysis

The healthcare sector of Asia Pacific varies immensely by countries. However, the Asia Pacific region has lower public sector expenditure and most treatments involve out of pocket expenditure. Further the eye care has been a neglected segment especially in the poor countries of Asia Pacific region. Japan and South Korea are the leading markets while China will be the fastest growing due to rising healthcare expenditure and faster economic growth. Also, the presence of strong generics especially in nations like India will lead to volume growth of anti-glaucoma drugs. The surgery market however will see fastest growth in Japan as compared to developing parts of Asia Pacific.

Asia-Pacific Glaucoma Treatment Market has been segmented on the basis of disease indication which comprises Closed Angle Glaucoma (CAG), open angle glaucoma (OAG), secondary glaucoma, congenital glaucoma and other. On the basis of drug class; market is segmented into prostaglandin analogs (PGAS), alpha agonist, beta blockers, cholinergic drugs, carbonic anhydrase inhibitors, and others. On the basis of surgery; market is segmented into laser iridotomy, laser trabeculoplasty, aqueous shunt surgery and peripheral iridectomy. On the basis of end users; market is segmented into hospitals and home users

Asia-Pacific Glaucoma Treatment Market – Segments

Asia-Pacific Glaucoma Treatment Market has been segmented on the basis of disease indication which comprises Closed Angle Glaucoma (CAG), open angle glaucoma (OAG), secondary glaucoma, congenital glaucoma and other. On the basis of drug class; market is segmented into prostaglandin analogs (PGAS), alpha agonist, beta blockers, cholinergic drugs, carbonic anhydrase inhibitors, and others. On the basis of surgery; market is segmented into laser iridotomy, laser trabeculoplasty, aqueous shunt surgery and peripheral iridectomy. On the basis of end users; market is segmented into hospitals and home users.

Browse Complete 70 Pages Premium Research Report Enabled with Tables and Figures @ https://www.marketresearchfuture.com/reports/asia-pacific-glaucoma-treatment-market-2962

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

Contact:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Maharashtra, India
+1 646 845 9312
Email: salesteam@marketresearchfuture.com

This release was published on openPR.